Literature DB >> 30318280

Outcomes of infants with congenital diaphragmatic hernia treated with venovenous versus venoarterial extracorporeal membrane oxygenation: A propensity score approach.

Yigit S Guner1, Matthew T Harting2, Kelly Fairbairn3, Patrick T Delaplain4, Lishi Zhang5, Yanjun Chen5, Mustafa H Kabeer6, Peter Yu6, John P Cleary7, James E Stein8, Charles Stolar9, Danh V Nguyen10.   

Abstract

PURPOSE: Previous studies comparing extracorporeal membrane oxygenation (ECMO) modality for congenital diaphragmatic hernia (CDH) have not accounted for confounding by indication. We therefore hypothesized that using a propensity score (PS) approach to account for selection bias may identify outcome differences based on ECMO modality for infants with CDH.
METHODS: We utilized ELSO Registry data (2000-2016). Patients with CDH were divided to either venoarterial (VA) or venovenous (VV) ECMO. Patients were matched by PS to control for nonrandom treatment assignment. Subgroup analyses were conducted based on timing of CDH repair relative to ECMO. Primary analysis was the "intent-to-treat" cohort based on the initial ECMO mode. Mortality was the primary outcome, and severe neurologic injury (SNI) was a secondary outcome.
RESULTS: PS matching (3:1) identified 3304 infants (VA = 2470, VV = 834). In the main group, mortality was not different between VA and VV ECMO (OR = 1.01, 95% CI: 0.86-1.18) and there was no difference in SNI between VA and VV (OR = 0.80; 95% CI: 0.63-1.01). For the pre-ECMO CDH repair subgroup, 175 VA cases were matched to 70 VV. In these neonates, mortality was higher for VV compared to VA (OR = 2.10, 95% CI: 1.19-3.69), without any difference in SNI (OR = 1.48; 95% CI: 0.59-3.71). For the subgroup that did not have pre-ECMO CDH repair, 2030 VA cases were matched to 683 VV cases. In this subgroup, VV was associated with 27% lower risk of SNI relative to VA (OR = 0.73, 95% CI: 0.56-0.95) without any difference in mortality (OR = 0.94, 95% CI: 0.79-1.11).
CONCLUSION: This study revalidates that ECMO mode does not significantly affect mortality or SNI in infants with CDH. In the subset of infants who require pre-ECMO CDH repair, VA favors survival, whereas, in the subgroup of infants that did not have pre-ECMO CDH repair, VV favors lower rates of SNI. We conclude that neither mode appears consistently superior across all situations, and clinical judgment should remain a multifactorial decision. LEVEL OF EVIDENCE: Level III.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CDH; ECMO; Propensity score; Venoarterial; Venovenous

Mesh:

Year:  2018        PMID: 30318280      PMCID: PMC6192269          DOI: 10.1016/j.jpedsurg.2018.06.003

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  20 in total

1.  Jugular vein hypoplasia can preclude extracorporeal membrane oxygenation cannulation in the neonate with congenital diaphragmatic hernia: potential identification of the neonate at risk by fetal magnetic resonance imaging.

Authors:  Christopher I Cassady; Amy R Mehollin-Ray; Oluyinka O Olutoye; Darrell L Cass
Journal:  Fetal Diagn Ther       Date:  2011-09-28       Impact factor: 2.587

2.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

Authors:  R B D'Agostino
Journal:  Stat Med       Date:  1998-10-15       Impact factor: 2.373

3.  Timing of repair of congenital diaphragmatic hernia in patients supported by extracorporeal membrane oxygenation (ECMO).

Authors:  Emily A Partridge; William H Peranteau; Natalie E Rintoul; Lisa M Herkert; Alan W Flake; N Scott Adzick; Holly L Hedrick
Journal:  J Pediatr Surg       Date:  2014-11-07       Impact factor: 2.545

4.  Venoarterial versus venovenous extracorporeal membrane oxygenation in congenital diaphragmatic hernia: the Extracorporeal Life Support Organization Registry, 1990-1999.

Authors:  R A Dimmitt; R L Moss; W D Rhine; W E Benitz; M C Henry; K P Vanmeurs
Journal:  J Pediatr Surg       Date:  2001-08       Impact factor: 2.545

5.  Indomethacin prophylaxis for preterm infants: the impact of 2 multicentered randomized controlled trials on clinical practice.

Authors:  Ronald I Clyman; Shampa Saha; Alan Jobe; William Oh
Journal:  J Pediatr       Date:  2007-01       Impact factor: 4.406

6.  Neurologic complications in neonates supported with extracorporeal membrane oxygenation. An analysis of ELSO registry data.

Authors:  Angelo Polito; Cindy S Barrett; David Wypij; Peter T Rycus; Roberta Netto; Paola E Cogo; Ravi R Thiagarajan
Journal:  Intensive Care Med       Date:  2013-06-08       Impact factor: 17.440

7.  High-frequency oscillatory ventilation versus conventional mechanical ventilation for very-low-birth-weight infants.

Authors:  Sherry E Courtney; David J Durand; Jeanette M Asselin; Mark L Hudak; Judy L Aschner; Craig T Shoemaker
Journal:  N Engl J Med       Date:  2002-08-29       Impact factor: 91.245

8.  Outcome analysis of neonates with congenital diaphragmatic hernia treated with venovenous vs venoarterial extracorporeal membrane oxygenation.

Authors:  Yigit S Guner; Robinder G Khemani; Faisal G Qureshi; Choo Phei Wee; Mary T Austin; Fred Dorey; Peter T Rycus; Henri R Ford; Philippe Friedlich; James E Stein
Journal:  J Pediatr Surg       Date:  2009-09       Impact factor: 2.545

Review 9.  Neurologic complications and neurodevelopmental outcome with extracorporeal life support.

Authors:  Amit Mehta; Laura M Ibsen
Journal:  World J Crit Care Med       Date:  2013-11-04

10.  Intraventricular hemorrhage and neurodevelopmental outcomes in extreme preterm infants.

Authors:  Srinivas Bolisetty; Anjali Dhawan; Mohamed Abdel-Latif; Barbara Bajuk; Jacqueline Stack; Kei Lui
Journal:  Pediatrics       Date:  2013-12-30       Impact factor: 7.124

View more
  1 in total

Review 1.  Congenital diaphragmatic hernia: a narrative review of controversies in neonatal management.

Authors:  Michelle J Yang; Katie W Russell; Bradley A Yoder; Stephen J Fenton
Journal:  Transl Pediatr       Date:  2021-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.